Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 2, 2015, Pages

  Bedenis, Rachel ^a   Lethaby, Anne ^b   Maxwell, Heather ^c   Acosta, Stefan ^d   Prins, Martin H ^e  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Department of Vascular Diseases ^*  (United Kingdom)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CARBASALATE CALCIUM; CLOPIDOGREL; COUMARIN; COUMARIN DERIVATIVE; DALTEPARIN; DIPYRIDAMOLE; HEPARIN; INDOBUFEN; LOW MOLECULAR WEIGHT HEPARIN; NAFTIDROFURYL; PENTOXIFYLLINE; PHENPROCOUMON; PLACEBO; PROSTAGLANDIN E1; TICLOPIDINE;

ARTERY SURGERY; ATHEROSCLEROSIS; BLEEDING; BYPASS SURGERY; CARDIOVASCULAR DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMORODISTAL BYPASS GRAFTING; FEMOROPOPLITEAL BYPASS; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; GRAFT INFECTION; GRAFT OCCLUSION; GRAFT PATENCY; LIMB AMPUTATION; LIMB SALVAGE; LOWER LIMB; MORTALITY; PERIPHERAL ARTERY BYPASS SURGERY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STOMACH HEMORRHAGE; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; VEIN GRAFT; VERTIGO; WOUND INFECTION; ADVERSE EFFECTS; ANASTOMOSIS; ARTERIOSCLEROSIS; GRAFT OCCLUSION, VASCULAR; HUMAN; INTERMITTENT CLAUDICATION; META ANALYSIS; PERIPHERAL VASCULAR DISEASES; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOSIS; VASCULAR PATENCY;

ANASTOMOSIS, SURGICAL; ANTICOAGULANTS; ARTERIOSCLEROSIS; ASPIRIN; DIPYRIDAMOLE; GRAFT OCCLUSION, VASCULAR; HUMANS; INTERMITTENT CLAUDICATION; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOSIS; VASCULAR PATENCY;

EID: 84965186521     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000535.pub3     Document Type: Review

References (71)

1. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. New England Journal of Medicine 1997;337(24):1726-31.
2. Algra A. A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg 1999; Vol. 77, issue 4:11.
3. Ariesen MJ, Tangelder MJD, Lawson JA, Eikelboom BC, Grobbee DE, Algra A. Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery 2005;30(2):154-9.
4. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet 2000;355(9201):346-51.
5. Eikelboom BC. Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde 2001;145(22):1060-7.
6. Oostenbrink JB, Tangelder MJ, Busschbach JJ, Van Hout BA, Buskens E, Algra A, et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery 2001;34(2):254-62.
7. Smeets L, Ho GH, Tangelder MJ, Algra A, Lawson JA, Eikelboom BC, et al. Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery 2005;30(6):604-9.
8. Tangelder MJ, Algra A, Lawson JA, Eikelboom BC. Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery 2000;20(2):118-24.
9. Tangelder MJ, Algra A, Lawson JA, Hennekes S, Eikelboom BC. Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery 2001;33(3):522-7.
10. Tangelder MJ, Eikelboom BC, Lawson JA, Algra A. Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde 1995;139(29):1504-6.
11. Tangelder MJ, McDonnel J, Van Busschbach JJ, Buskens E, Algra A, Lawson JA, Eikelboom BC. Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery 1999;29(5):913-9.
12. Van Hattum ES, Algra A, Lawson JA, Eikelboom BC, Moll FL, Tangelder MJD. Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation 2009;120(16):1569-76.
13. Van Hattum ES, Tangelder MJD, Lawson JA, Moll FL, Algra A. The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery 2011;53(3):643-50.
14. Anonymous . Clopidogrel and acetyl salicylic acid in bypass surgery for peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT00174759?term=CASPAR&rank=2 (accessed 5 May 2014).
15. Anonymous . Dual antiplatelet therapy benefits prosthetic but not venous grafts. Vascular News 2009;Feb:17.
16. Belch JJ, Dormandy J. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery 2010;52(4):825-33.
17. The Caspar Investigators, Belch J. Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomised placebo controlled study. Vascular Annual Meeting; 2007 Jun; Baltimore, USA. 2007.
18. Clyne CA, Archer TJ, Atuhaire LK, Chant AD, Webster JH. Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery 1987;74(4):246-8.
19. D'Addato M, Curti T, Bertini D, Donini I, Ferrero R, Fiorani P, et al. Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. International Angiology 1992;11(2):106-12.
20. Donaldson DR, Salter MC, Kester RC, Rajah SM, Hall TJ, Sreeharan N, et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery 1985;19(4):224-30.
21. Edmondson RA, Cohen AT, Das SK, Wagner BM, Kakkar VV. Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994;344(8927):914-8.
22. Goldman M, McCollum C. A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery 1984;18(4):217-21.
23. Green RM, Roedersheimer RL, DeWeese JA. Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery 1982;92(6):1016-26.
24. Gruss JD, Hiemer W, Kroiss A, Geissler C. Experiences with adjuvant prostaglandin therapy in vascular surgery interventions. Vasa-Supplementum 1991;33:353-4.
25. Kohler TR, Kaufman JL, Kacoyanis G, Clowes A, Donaldson MC, Kelly E, et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery 1984;96(3):462-6.
26. Lucas MA. Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology 1984;35(7):443-50.
27. Franks PJ, Sian M, Kenchington GF, Alexander CE, Powell JT. Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery 1992;6(2):185-8.
28. Franks PJ, Sian M, Kenchington GF, Alexander CE, Powell JT. Aspirin usage and its influence on femoropopliteal vein graft patency. European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991.
29. McCollum C, Alexander C, Kenchington G, Franks PJ, Greenhalgh R. Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery 1991;13(1):150-62.
30. Powell JT, Greenhalgh RM. Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae 1992;81(2):236-41.
31. Noppeney T, Kasprzak P, Raithel D, Hirche H. Naftidrofuryl in postoperative treatment after femoropopliteal bypass. Die Medizinische Welt 1988;39:1545-50.
32. Raithel D. Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery 1987;21(3):208-14.
33. Raithel D, Kasprzak P, Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt 1986;37:664-7.
34. Schneider E, Brunner U, Bollinger A. No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio 1979;2(1):73-7.
35. Böhmig HJ, Zeidler G, Schwierz TH, Loy E. Orthograde vein bypass procedure for inguinal arterial reconstructions - 20 years experience [20 Jahre orthograder venen-bypass für infrainguinale arterielle rekonstruktion]. Chirurg 1995;66(2):120-6.
36. Burdess A, Nimmo A, Garden OJ, Murie JA, Dawson AR, Fox KA, et al. Dual antiplatelet therapy in surgery for critical limb ischaemia. The Vascular Society of Great Britain & Ireland Yearbook 2008 2008:47.
37. Burdess A, Nimmo AF, Garden OJ, Murie JA, Dawson AR, Fox KA, et al. Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. Annals of Surgery 2010;252(1):37-42.
38. DeWeese JA, Rob CG. Autogenous venous bypass grafts five years later. Annals of Surgery 1971;174(3):346-56.
39. Ehresmann U, Alemany J, Loew D. Use of acetylsalicylic acid in the prevention of re-occlusion following revascularization interventions. Results of a double blind long term study [Prophylaxe von rezidivverschlüssen nach revaskularisationseingriffen mit acetylsalicylsäure]. Medizinische Welt 1977;28(26):1157-62.
40. EUCTR2007-003746-15-DE . Prospective randomized open study on the comparison of fondaparinux with the low-molecular-weight heparin enoxaparin in patients undergoing femoro-distal venous bypass operation. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003746-15/DE 2008.
41. Gorter JW, Oostenbrink JB, Tangelder MJ, Stroke Pi, Reversible Ischemia Trial (SPIRIT) Study Group, Dutch Bypass O, Anticoagulants or Aspirin Study (BOA). Costs of outpatient anticoagulant treatment in patients with cerebral and peripheral arterial occlusive disease. Thrombosis and Haemostasis 2001;85(1):52-6.
42. Harjola PT, Meurala H, Frick MH. Prevention of early reocclusion by dipyridamole and ASA in arterial reconstructive surgery. Journal of Cardiovascular Surgery 1981;22(2):141-4.
43. Jivegard L, Drott C, Gelin J, Groth O, Hensater M, Jensen N, et al. Effects of three months of low molecular weight heparin (Dalteparin) treatment after bypass surgery for lower limb ischemia - A randomised placebo-controlled double blind multicentre trial. European Journal of Vascular and Endovascular Surgery 2005;29(2):190-8.
44. Johnson WC, Williford WO, Department of Veterans Affairs Cooperative Study # 362. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. Journal of Vascular Surgery 2002;35(3):413-21.
45. Johnson WC, Williford WO, Corson JD, Padberg FT Jr. Hemorrhagic complications during long-term postoperative warfarin administration in patients undergoing lower extremity arterial bypass surgery. Vascular 2004;12(6):362-8.
46. Kibbe MR, Hassett AL, McSherry F, Conner P, Bontempo FA, Williford W, et al. Can screening for genetic markers improve peripheral artery bypass patency?. Journal of Vascular Surgery 2002;36(6):1198-206.
47. Lassila R, Lepäntalo M, Lindfors O. The effect of acetylicsalicylic acid on the outcome after lower limb arterial surgery with special reference to cigarette smoking. World Journal of Surgery 1991;15(3):378-82.
48. Monaco M, Di Tommaso L, Pinna GB, Lillo S, Schiavone V, Stassano P. Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients. Journal of Vascular Surgery 2012;56(1):96-105.
49. Nevelsteen A, Mortelmans L, Van de Cruys A, Merckx E, Verhaeghe R. Effect of ticlopidine on blood loss, platelet turnover and platelet deposition on prosthetic surfaces in patients undergoing aorto-femoral bypass grafting. Thrombosis Research 1991;64(3):363-9.
50. Raithel D, Noppeney T, Kasprzak P. [Medikamentöse Therapie nach femoro.poplitealem Kunststoffbypass - naftidrofuryl versus ASS]. Vasa-Supplementum. 1987; Vol. 20:223-Abstract No 78.
51. Reichle FA, Rankin KP, Tyson RR, Finestone AJ, Shuman C. Long-term results of 474 arterial reconstructions for severely ischemic limbs: A fourteen year follow-up. Surgery 1979;85(1):93-100.
52. Rosenthal D, Mittenthal MH, Ruben DM, Jones DH, Estes JW, Stanton PE, et al. The effects of aspirin, dipyridamole and warfarin in femorodistal reconstruction: long-term results. American Surgeon 1987;53(9):477-81.
53. Satiani B. A prospective randomized trial of aspirin in femoral popliteal and tibial bypass grafts. Angiology 1985;36(9):608-16.
54. Shionoya S, Sakurai T, Ueyama T, Kusakawa M, Sakaguchi S, Tsuchioka H, et al. Effect of ticlopidine on graft patency following arterial reconstructive surgery in the lower extremity: a multicenter three-year prospective study. Vascular Surgery 1990;24(8):541-7.
55. Smout JD, Mikhailidis DP, Shenton BK, Stansby G. Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. Clinical and Applied Thrombosis/Hemostasis 2004;10(1):9-18.
56. Abbott WM, Green RM, Matsumoto T, Wheeler JR, Miller N, Veith FJ, et al. Prosthetic above-knee femoropopliteal bypass grafting: results of a multicenter randomized prospective trial. Above-Knee Femoropopliteal Study Group. Journal of Vascular Surgery 1997;25(1):19-28.
57. Baril D, Patel V, Judelson D, Goodney P, McPhee J, Hevelone N, et al. Outcomes of lower extremity bypass performed for acute limb ischemia. Journal of Vascular Surgery 2013;58(4):949-56.
58. Becker F, Robert-Ebadi H, Ricco JB, Setacci C, Cao P, De Donato G. Guidelines for critical limb ischaemia and diabetic foot, Chapter I: Definitions, Epidemiology, Clinical presentation and Prognosis. European Journal of Vascular and Endovascular Surgery 2011;42:4-12.
59. European Working Group on Critical Limb Ischemia. Second European Consensus Document on Chronic Critical Leg Ischemia. Second European Consensus Document on Chronic Critical Leg Ischemia. Circulation 1991;84 Suppl 4:1-26.
60. Cooper GG, Austin C, Fitzsimmons E, Brannigan PD, Hood JM, D'Sa AA. Outflow resistance and early occlusion of infrainguinal bypass grafts. European Journal of Vascular Surgery 1990;4(3):279-83.
61. Fujitani RM, Nordestgaard AG, Marcus CS, Wilson SE. Perioperative suppression of platelet adherence to small-diameter polytetrafluoroethylene (PTFE) grafts. Journal of Surgical Research 1988;44(4):455-60.
62. Geraghty AJ, Welch K. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD000536.pub2]
63. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
64. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
65. Anon . Antiplatelet treatment- summary. National Institue for Health and Care Excellence (NICE) 2013; Vol. cks.nice.org.uk/antiplatelet-treatment#!topicsummary, issue (Accessed July 1 2014).
66. Rutherford RB, Jones DN, Bergentz SE, Bergqvist D, Comerota AJ, Dardik H, et al. Factors affecting the patency of infrainguinal bypass. Journal of Vascular Surgery 1988;8(3):236-46.
67. Tangelder MJ, Lawson JA, Algra A, Eikelboom BC. Systematic review of randomized controlled trials of aspiring and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. Journal of Vascular Surgery 1999;30(4):701-9.
68. Tangelder MJ, Algra A, Lawson JA, Eikelboom, BC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery 2000;20(2):118-24.
69. Adams D, Stonebridge PA. Antiplatelet therapy after peripheral arterial bypass surgery. Cochrane Database of Systematic Reviews 1997, Issue 4. [DOI: 10.1002/14651858.CD000535]
70. Brown J, Lethaby A, Maxwell H, Wawrzyniak AJ, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD000535.pub2]
71. Dörffler-Melly J, Büller HR, Koopman MM, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD000535]